Advertisement

Topics

Amylin Sues Eli Lilly, Arguing Breach of Contract in Marketing Rival Diabetes Drug

10:04 EDT 16 May 2011 |

[Updated: 8:55 am PT] Amylin Pharmaceuticals is hauling one of its big partners, Eli Lilly, into court. San Diego-based Amylin (NASDAQ: AMLN) said today it has filed a suit in the U.S. District Court for Southern California, that accuses Lilly of anticompetitive behavior and violating a 2002 agreement between the companies that covers the marketing [...]

Original Article: Amylin Sues Eli Lilly, Arguing Breach of Contract in Marketing Rival Diabetes Drug

NEXT ARTICLE

More From BioPortfolio on "Amylin Sues Eli Lilly, Arguing Breach of Contract in Marketing Rival Diabetes Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...